Parathyroid Hormone (1–84)
Also referenced as: Natpara, Recombinant human PTH 1-84
A full-length recombinant PTH medicine with historical approval and subsequent supply discontinuation.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- FDA Approved for Specific Indication
Natpara was FDA-approved as an adjunct to calcium and vitamin D in selected hypoparathyroidism patients, but is discontinued and no longer supplied through the US Special Use Program.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A full-length recombinant PTH medicine with historical approval and subsequent supply discontinuation.
Natpara was FDA-approved as an adjunct to calcium and vitamin D in selected hypoparathyroidism patients, but is discontinued and no longer supplied through the US Special Use Program.
Manufacturing ended in 2024 and the US Special Use Program closed at the end of 2025. Supply discontinuation is not itself evidence of formal approval withdrawal.
Why It's Being Studied
- Hypoparathyroidism
- Historical PTH replacement
Mechanism of Action
PTH-receptor activation supports calcium regulation and interacts with bone and kidney physiology.
PTH-receptor activation supports calcium regulation and interacts with bone and kidney physiology. Manufacturing ended in 2024 and the US Special Use Program closed at the end of 2025. Supply discontinuation is not itself evidence of formal approval withdrawal.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Hypoparathyroidism
- Historical PTH replacement
- Historical subcutaneous approved medicine
Evidence Summary
Human trials supported a selected hypoparathyroidism adjunct indication; manufacturing and supply history now constrain availability.
Higher tiers carry more weight. Filled tiers have evidence for Parathyroid Hormone (1–84); tap to read it.
- Human trials supported a selected hypoparathyroidism adjunct indication; manufacturing and supply history now constrain availability.
1 cited sources.
- Regulatory document1
Human clinical evidence
- Human trials supported a selected hypoparathyroidism adjunct indication; manufacturing and supply history now constrain availability.
Reported Adverse Events in Research
- Abrupt cessation can cause severe hypocalcemia; historical labeling included important osteosarcoma-related precautions.
Limitations of Current Evidence
- Manufacturing ended in 2024 and the US Special Use Program closed at the end of 2025. Supply discontinuation is not itself evidence of formal approval withdrawal.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Parathyroid Hormone (1–84) | Trofinetide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Historical subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
Parathyroid Hormone (1–84) — regulatory document